Consortium of Broad-spectrum jumbo bacteriophages for control of multidrug resistant Pseudomonas aeruginosa

IN607677BActive Publication Date: 2026-10-29NITTE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202141044837
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-10-04
Publication Date
2026-10-29
Estimated Expiration
2041-10-04

AI Technical Summary

Technical Problem

The emergence of highly virulent multidrug-resistant Pseudomonas aeruginosa has created a need for alternative therapies, as individual phages have limited spectrum of activity and existing treatments are ineffective against biofilm-forming and multidrug-resistant strains.

Method used

A consortium of three broad-spectrum jumbo lytic phages (ɸT2, ɸU1b, and ɸU5) with a broad host range was isolated and characterized, demonstrating high lytic activity against Pseudomonas aeruginosa from diverse sources, including clinical and environmental isolates, and were found to effectively reduce biofilm density and bacterial growth.

Benefits of technology

The phage consortium efficiently reduces the viable cell count and biofilm density of Pseudomonas aeruginosa, showing stability across various temperatures and pH levels, and is effective against multidrug-resistant strains, making them suitable alternatives to antibiotics for treating severe infections.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

ABSTRACT Consortium of broad-spectrum jumbo bacteriophages for control of multidrug resistant Pseudomonas aeruginosa The emergence of highly virulent multidrug-resistant Plasmodium aeruginosa has become increasingly evident among hospital acquired infections and has raised the need for alternative therapies. Phage therapy can be one such alternative to antibiotic therapy to combat multidrug-resistant pathogenic bacteria, but this requires the availability of phages with a broad host range. The consortium of jumbo bacteriophages could be a potential candidate for combating infectious disease caused by biofilm forming, multidrug resistant P. aeruginosa. We have isolated and characterized a consortium of jumbo P. aeruginosa phages that have a very broad spectrum of activity for the control of Multidrug resistant P. aeruginosa. Three new jumbo lytic P. aeruginosa specific broad host range phages were isolated and characterised in this present study belonged to the family Myoviridae (order Caudovirales). The consortium developed by us could control biofilm formation by diverse P. aeruginosa strains from diverse sources.
Need to check novelty before this filing date? Find Prior Art

Description

1. PREAMBLE TO THE DESCRIPTIONThe emergence of highly virulent multidrug-resistant P. aeruginosa has becomeincreasingly evident among hospital acquired infections and has raised the need foralternative therapies. Phage therapy can be one such alternative to antibiotic therapyto combat multidrug-resistant pathogenic bacteria, but this requires the availability ofphages with a broad host range. Individual phages have limited spectrum of activity.We have isolated, characterized and developed a consortium of P. aeruginosa phages(Three new jumbo lytic phages) that have a very broad spectrum of activity. Thegenetic analysis of ɸU5 revealed that phage has a genome size of 282.6 kbp with 373putative open reading frames (ORFs), and its genetic architecture is similar to phiKZlike jumbo phages infecting P. aeruginosa. The bacteriophages isolated in this studyhad lytic ability against biofilm-forming and multidrug-resistant P. aeruginosa fromdifferent sources and could be candidates for phage therapy.ObjectiveIsolation and purification of broad-spectrum Pseudomonas aeruginosa phages forphage therapy of diverse Pseudomonas aeruginosa from different environments andmolecular characterization of isolated Pseudomonas aeruginosa phagesHighlightsPseudomonas aeruginosa specific phages were isolated from sewage samples usingP. aeruginosa PAO1 as bait and molecular characterization was carried out. A total of17 phages isolated, showed different spectra of activity and efficiency of lysis against82 isolates of P. aeruginosa obtained from clinical samples (n=13), hospital effluent(n=46) and fish processing plant effluent (n=23). All these phages were tested fortheir lytic activity against PAO1 strain and as shown in Fig. 1, Plaque forming unit ofthese phages were determined by plaque assay (Fig. 1). The plaques formed wereuniform, transparent round zones about 1.5-2.5 mm in diameter (Fig. 1b). High titrephages (7.6×108 to 3.04×1011 PFU / ml) with varied morphology (n=17) were selectedfor the host range analysis. In the host range analysis, P. aeruginosa isolated fromboth environmental and clinical sources were included in order to study the extent oflytic spectrum. Out of five phages, ɸT2, ɸU1b, and ɸU5 had the maximum hostrange, and could lyse more than 75 % of the P. aeruginosa strains examined in thisstudy and used for further characterization (Table 1). These phages were successfullypropagated in confluent plates by the scrape lysate method following propagation in100 ml of LB broth, which yielded a high titre of the phages. The phage code,number of bacterial isolates and the percentage of P. aeruginosa isolates infected aredetailed in supplementary Table 1.One-step growth curves were determined for phages ɸT2, ɸU1b and ɸU5 with midlogarithmic-phase host cells. The ɸT2 had a burst size of 88 PFU per cell and a latentperiod of 30 min. Phage ɸU1b had a burst size of 227 PFU per cell and a latent periodof 30 min. Phage ɸU5 had a burst size of 260 PFU per cell and a latent period of 20min. This result shows efficient lytic development of the phages (ɸT2, ɸU1b andɸU5) (Fig. 2).The lysis activity of ɸT2, ɸU1b and ɸU5 were tested on the host P. aeruginosa PAO1at early phase (Fig. 3). The three-candidate phages were able to efficiently reduce theviable cell count of the host P. aeruginosa PAO1 in broth at 0.01 and lower MOI asindicated by a decrease in the optical density of the infected culture compared tocontrol up to 6 h. The ɸU1b was stable at 25°C and 4°C for a period of 24 h, while adecrease in titres was observed at all other temperatures (Fig. 4). Based on this, pHstability at 25°C was tested, and the phage was stable at pH 7 for up to 24 h, while 10log lower numbers were recovered at pH 3 and pH 5, and alkaline pH of 9 and 11 wasdetrimental for the phage (Fig. 4).We tested the infective capability of the cocktail (consortium) containing threephages against P. aeruginosa PAO1 in vitro. As shown in Figure 5, cocktail of all thethree phages were found to be efficient in reducing bacterial growth of P. aeruginosaPAO1 and lasted for at least 12 h.Among the five phages, three (ɸU5, ɸU1b and T2) were examined by electronmicroscopy to study their morphological features (Fig. 6). All these phages hadicosahedral heads and contractile tails and were grouped under the order of tailedphages, Caudovirales. Further analysis of TEM images revealed that all the phageshad a head length measuring about 121 ± 3 nm diameter and contractile tails with adiameter of 30 nm and a length of 210 nm. Based on the morphometric analysis, it isconcluded that all three phages belong to the family Myoviridae. An interestingobservation from this analysis is their unusual size as compared to the mostcharacterised Pseudomonas phages.Biofilm forming ability of P. aeruginosa and phage susceptibilityAs P. aeruginosa is an opportunistic pathogenic bacterium responsible for both acuteand chronic infections due to its ability to form biofilms, its tolerance and resistanceto clinically significant antibiotics are worrisome. Here, we have investigated theability of three phages (ɸT2, ɸU1b and ɸU5) to reduce the biofilm density ofdifferent isolates (n=46) categorised as strong biofilm formers (n=27) and moderatebiofilm formers (n=19) as per microtiter plate assay (Fig. 6). The three phages (ɸT2,ɸU1b and ɸU5) were able to remove biofilms formed by the P. aeruginosa isolatesbetter at lower MOI. Since drug-resistant P. aeruginosa is one of the importantcauses of wound infection in humans, the Pseudomonas specific bacteriophagesisolated and characterised in this study could be used as alternatives to antibiotics totreat such severe infections. The findings of this study support the potential of theconsortium of phages could be used in controlling the highly pathogenic P.aeruginosa strains irrespective of their drug susceptibility pattern.The complete genome sequence of the phage ɸU5 that showed the highest lyticactivity against P. aeruginosa was determined using Illumina HiSeq sequencingplatform. The nucleotide sequence was assembled into a contig of 282,684 bp(GenBank accession no. MT995928). The ɸU5 genome had a GC content of 36.9%,which is similar to P. aeruginosa phage phiKZ. The genetic architecture and thecontent of ɸU5 resemble that of the P. aeruginosa jumbo phage KTN4 and phiKZ.The analysis of ɸU5 using PhageTerm revealed that the genome is circular andterminally redundant with Mu packaging. A typical genome map highlighting majorgenetic segments of ɸU5 is shown in Figure 8. A total of 373 open reading frames(ORFs) were predicted from the draft genome sequence ranging in size from 73 bp to6,714 bp, which consists of 27 structural proteins, 34 genes coding for thefunctionality of the phage and 306 are annotated as hypothetical proteins. Most of theORFs were predicted to start with AUG codon, and few ORFs were started withGUG (ORFs 16, 52, 73, 82, 138, 164, 252, 296 and 367) or UUG (ORFs 168 and198) codons. Six tRNA genes were predicted in the phage genome and encoded forMet (AUG), Thr (ACA), Asn (AAC), Asp (GAC), Leu (TTA) and Pro (CCA) (Fig.8). To determine the similarity of the ɸU5 genome to the previously described jumbophage sequences of KTN4 and phiKZ available in the GenBank until December 2017,an all-versus-all comparison was performed. Comparative analysis revealed thatphages U5, KTN4 (GenBank accession no. KU521356) and phiKZ (GenBankaccession no. NC004629) shared similar ORF content. Further, the intergenomicsimilarity calculated using VIRIDIC tool revealed that the genome of ɸU5 is closelyrelated to the genome of KTN4 and phiKZ with similarity of 94.6 % and 94.5 %respectively. Phylogenetic analysis of capsid protein revealed that the newly isolatedU5 phage clustered within the already classified Pseudomonas-specific jumbo phagesreported by other investigators. Within the cluster, ɸU5 is evolutionarily highlysimilar to the Pseudomonas phiKZ phage.Antibiogram analysisThe antibiogram of the isolates revealed that among 82 P. aeruginosa isolates, 61(74.4%) isolates were found to be multidrug-resistant (MDR) i.e which showedresistance to three or more class of antibiotics. Highest resistance was observed forampicillin at 87.8%, followed by nalidixic acid (73.1%), nitrofurantoin (63.4%),cotrimaxozole (44%), and cefotaxime (43.9%) and lowest towards ceftazidime(1.2%). All the P. aeruginosa isolated (100%) from the clinical cases were found tobe MDR, whereas 86.95% of isolates obtained from the hospital effluent run off wereMDR. Antibiogram analyses of all the isolates used in the present study are shown inFig. 9.Thus, we have demonstrated that the consortium developed by us has ability to lyseMDR Pseudomonas aeruginosa from diverse sources.

Claims

1. We have developed a consortium of three new jumbo lytic bacteriophages ɸT2, ɸU1b and ɸU5 against multidrug resistant Plasmodium aeruginosa were isolated from diverse sources.

2. We have characterized the phages and demonstrated that they have a very broad spectrum of antibacterial activity.

3. The three phages (ɸT2, ɸU1b and ɸU5) mentioned in claim 1 were able to remove biofilms formed by the P. aeruginosa isolates at low Multiplicity of Infection (MOI).

4. Consortium of P. aeruginosa phages mentioned in claim 1 prevents emergence of phage resistance in P. aeruginosa due to cross lytic activity